{# ── Billing problem banner: payment failed (past_due) or retries exhausted (unpaid). Pro access is gated off by is_pro until the card is fixed, so prompt the user to update billing. ── #}
NASDAQ: ZNTL Zentalis Pharmaceuticals, Inc. 8-K

Zentalis reports 39% response rate in Phase 1b ovarian cancer trial, optimal dose shows 50% ORR

Filed May 21, 2026 · Period ending May 21, 2026 · ~1 min read

4 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade ZNTL commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Feedback
View original filing on SEC.gov

Generated by AI · May 27, 2026 7:05 AM